{"id":3768,"date":"2026-06-05T09:32:20","date_gmt":"2026-06-05T16:32:20","guid":{"rendered":"https:\/\/xpharma.com.cn\/?p=3768"},"modified":"2026-06-05T09:32:21","modified_gmt":"2026-06-05T16:32:21","slug":"lupeng%ef%bc%9arocbrutinib-received-marketing-approval","status":"publish","type":"post","link":"https:\/\/xpharma.com.cn\/index.php\/news\/lupeng%ef%bc%9arocbrutinib-received-marketing-approval\/","title":{"rendered":"Lupeng\uff1aRocbrutinib\u00a0received marketing approval"},"content":{"rendered":"\n<figure class=\"wp-block-image size-full is-resized\"><img fetchpriority=\"high\" decoding=\"async\" width=\"802\" height=\"354\" src=\"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/202507041435387610.png\" alt=\"Lupeng\" class=\"wp-image-3769\" style=\"object-fit:contain;width:420px;height:310px\" srcset=\"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/202507041435387610.png 802w, https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/202507041435387610-300x132.png 300w, https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/202507041435387610-768x339.png 768w, https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/202507041435387610-500x221.png 500w\" sizes=\"(max-width: 802px) 100vw, 802px\" \/><figcaption class=\"wp-element-caption\">Lupeng<\/figcaption><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Lupeng Pharmaceutical&#8217;s BTK inhibitor Rocbrutinib granted priority review and conditional approval<\/strong><strong>.<\/strong><strong><\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Rocbrutinib is the world&#8217;s first fourth-generation BTK inhibitor with a dual covalent and non-covalent binding mechanism. It was developed by Lupeng Pharmaceutical using its proprietary BeyondX\u00ae platform and is specifically designed to overcome resistance to BTK inhibitors. It has the potential to become a best-in-class (BIC) therapy.<strong><\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Compared with first-generation BTK inhibitors, Rocbrutinib achieves a mechanism upgrade: it binds covalently to wild-type BTK and reversibly to resistance mutations such as C481S\/F\/R, while also irreversibly targeting the T474I gatekeeper mutation. This comprehensively overcomes drug resistance, with higher potency and greater selectivity. The currently approved indication is for adult patients with relapsed or refractory mantle cell lymphoma (R\/R MCL) who have previously received BTK inhibitor therapy.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Buy Rocbrutinib&nbsp;online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lupeng Pharmaceutical&#8217;s BTK inhibitor Rocbrutinib granted priority review and conditional approval. Rocbrutinib is the world&#8217;s first fourth-generation BTK inhibitor with a dual covalent and non-covalent binding mechanism. It was developed by Lupeng Pharmaceutical using its proprietary BeyondX\u00ae platform and is specifically designed to overcome resistance to BTK inhibitors. It has the potential to become a [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"class_list":["post-3768","post","type-post","status-publish","format-standard","hentry","category-news"],"blocksy_meta":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lupeng\uff1aRocbrutinib\u00a0received marketing approval - Xpharma China<\/title>\n<meta name=\"description\" content=\"Lupeng\uff1aRocbrutinib\u00a0received marketing approval - Xpharma China\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/xpharma.com.cn\/index.php\/news\/lupeng\uff1arocbrutinib-received-marketing-approval\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lupeng\uff1aRocbrutinib\u00a0received marketing approval - Xpharma China\" \/>\n<meta property=\"og:description\" content=\"Lupeng\uff1aRocbrutinib\u00a0received marketing approval - Xpharma China\" \/>\n<meta property=\"og:url\" content=\"https:\/\/xpharma.com.cn\/index.php\/news\/lupeng\uff1arocbrutinib-received-marketing-approval\/\" \/>\n<meta property=\"og:site_name\" content=\"Xpharma China\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/61590027634719\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-05T16:32:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-05T16:32:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/202507041435387610.png\" \/>\n\t<meta property=\"og:image:width\" content=\"802\" \/>\n\t<meta property=\"og:image:height\" content=\"354\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"xpharmanews\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Xpharma007\" \/>\n<meta name=\"twitter:site\" content=\"@Xpharma007\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"xpharmanews\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/lupeng%ef%bc%9arocbrutinib-received-marketing-approval\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/lupeng%ef%bc%9arocbrutinib-received-marketing-approval\\\/\"},\"author\":{\"name\":\"xpharmanews\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/person\\\/c292b26c0a3311036ce0f5ab28a1ea05\"},\"headline\":\"Lupeng\uff1aRocbrutinib\u00a0received marketing approval\",\"datePublished\":\"2026-06-05T16:32:20+00:00\",\"dateModified\":\"2026-06-05T16:32:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/lupeng%ef%bc%9arocbrutinib-received-marketing-approval\\\/\"},\"wordCount\":171,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/lupeng%ef%bc%9arocbrutinib-received-marketing-approval\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/202507041435387610.png\",\"articleSection\":[\"Approved News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/lupeng%ef%bc%9arocbrutinib-received-marketing-approval\\\/#respond\"]}]},{\"@type\":[\"WebPage\",\"MedicalWebPage\"],\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/lupeng%ef%bc%9arocbrutinib-received-marketing-approval\\\/\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/lupeng%ef%bc%9arocbrutinib-received-marketing-approval\\\/\",\"name\":\"Lupeng\uff1aRocbrutinib\u00a0received marketing approval - Xpharma China\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/lupeng%ef%bc%9arocbrutinib-received-marketing-approval\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/lupeng%ef%bc%9arocbrutinib-received-marketing-approval\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/202507041435387610.png\",\"datePublished\":\"2026-06-05T16:32:20+00:00\",\"dateModified\":\"2026-06-05T16:32:21+00:00\",\"description\":\"Lupeng\uff1aRocbrutinib\u00a0received marketing approval - Xpharma China\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/lupeng%ef%bc%9arocbrutinib-received-marketing-approval\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/lupeng%ef%bc%9arocbrutinib-received-marketing-approval\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/lupeng%ef%bc%9arocbrutinib-received-marketing-approval\\\/#primaryimage\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/202507041435387610.png\",\"contentUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/202507041435387610.png\",\"width\":802,\"height\":354,\"caption\":\"Lupeng\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/lupeng%ef%bc%9arocbrutinib-received-marketing-approval\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9875\",\"item\":\"https:\\\/\\\/xpharma.com.cn\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lupeng\uff1aRocbrutinib\u00a0received marketing approval\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#website\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/\",\"name\":\"Xpharma China - International Pharmaceutical wholesaler and retailer\",\"description\":\"Xpharma China\",\"publisher\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/xpharma.com.cn\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\",\"name\":\"Xpharma China\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/logo.gif\",\"contentUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/logo.gif\",\"width\":679,\"height\":166,\"caption\":\"Xpharma China\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/61590027634719\\\/\",\"https:\\\/\\\/x.com\\\/Xpharma007\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/person\\\/c292b26c0a3311036ce0f5ab28a1ea05\",\"name\":\"xpharmanews\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"caption\":\"xpharmanews\"},\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/author\\\/xpharmanews\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lupeng\uff1aRocbrutinib\u00a0received marketing approval - Xpharma China","description":"Lupeng\uff1aRocbrutinib\u00a0received marketing approval - Xpharma China","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/xpharma.com.cn\/index.php\/news\/lupeng\uff1arocbrutinib-received-marketing-approval\/","og_locale":"en_US","og_type":"article","og_title":"Lupeng\uff1aRocbrutinib\u00a0received marketing approval - Xpharma China","og_description":"Lupeng\uff1aRocbrutinib\u00a0received marketing approval - Xpharma China","og_url":"https:\/\/xpharma.com.cn\/index.php\/news\/lupeng\uff1arocbrutinib-received-marketing-approval\/","og_site_name":"Xpharma China","article_publisher":"https:\/\/www.facebook.com\/61590027634719\/","article_published_time":"2026-06-05T16:32:20+00:00","article_modified_time":"2026-06-05T16:32:21+00:00","og_image":[{"width":802,"height":354,"url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/202507041435387610.png","type":"image\/png"}],"author":"xpharmanews","twitter_card":"summary_large_image","twitter_creator":"@Xpharma007","twitter_site":"@Xpharma007","twitter_misc":{"Written by":"xpharmanews","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/lupeng%ef%bc%9arocbrutinib-received-marketing-approval\/#article","isPartOf":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/lupeng%ef%bc%9arocbrutinib-received-marketing-approval\/"},"author":{"name":"xpharmanews","@id":"https:\/\/xpharma.com.cn\/#\/schema\/person\/c292b26c0a3311036ce0f5ab28a1ea05"},"headline":"Lupeng\uff1aRocbrutinib\u00a0received marketing approval","datePublished":"2026-06-05T16:32:20+00:00","dateModified":"2026-06-05T16:32:21+00:00","mainEntityOfPage":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/lupeng%ef%bc%9arocbrutinib-received-marketing-approval\/"},"wordCount":171,"commentCount":0,"publisher":{"@id":"https:\/\/xpharma.com.cn\/#organization"},"image":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/lupeng%ef%bc%9arocbrutinib-received-marketing-approval\/#primaryimage"},"thumbnailUrl":"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/202507041435387610.png","articleSection":["Approved News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/xpharma.com.cn\/index.php\/news\/lupeng%ef%bc%9arocbrutinib-received-marketing-approval\/#respond"]}]},{"@type":["WebPage","MedicalWebPage"],"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/lupeng%ef%bc%9arocbrutinib-received-marketing-approval\/","url":"https:\/\/xpharma.com.cn\/index.php\/news\/lupeng%ef%bc%9arocbrutinib-received-marketing-approval\/","name":"Lupeng\uff1aRocbrutinib\u00a0received marketing approval - Xpharma China","isPartOf":{"@id":"https:\/\/xpharma.com.cn\/#website"},"primaryImageOfPage":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/lupeng%ef%bc%9arocbrutinib-received-marketing-approval\/#primaryimage"},"image":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/lupeng%ef%bc%9arocbrutinib-received-marketing-approval\/#primaryimage"},"thumbnailUrl":"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/202507041435387610.png","datePublished":"2026-06-05T16:32:20+00:00","dateModified":"2026-06-05T16:32:21+00:00","description":"Lupeng\uff1aRocbrutinib\u00a0received marketing approval - Xpharma China","breadcrumb":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/lupeng%ef%bc%9arocbrutinib-received-marketing-approval\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/xpharma.com.cn\/index.php\/news\/lupeng%ef%bc%9arocbrutinib-received-marketing-approval\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/lupeng%ef%bc%9arocbrutinib-received-marketing-approval\/#primaryimage","url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/202507041435387610.png","contentUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/06\/202507041435387610.png","width":802,"height":354,"caption":"Lupeng"},{"@type":"BreadcrumbList","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/lupeng%ef%bc%9arocbrutinib-received-marketing-approval\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9875","item":"https:\/\/xpharma.com.cn\/"},{"@type":"ListItem","position":2,"name":"Lupeng\uff1aRocbrutinib\u00a0received marketing approval"}]},{"@type":"WebSite","@id":"https:\/\/xpharma.com.cn\/#website","url":"https:\/\/xpharma.com.cn\/","name":"Xpharma China - International Pharmaceutical wholesaler and retailer","description":"Xpharma China","publisher":{"@id":"https:\/\/xpharma.com.cn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/xpharma.com.cn\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/xpharma.com.cn\/#organization","name":"Xpharma China","url":"https:\/\/xpharma.com.cn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/xpharma.com.cn\/#\/schema\/logo\/image\/","url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/logo.gif","contentUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/logo.gif","width":679,"height":166,"caption":"Xpharma China"},"image":{"@id":"https:\/\/xpharma.com.cn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/61590027634719\/","https:\/\/x.com\/Xpharma007"]},{"@type":"Person","@id":"https:\/\/xpharma.com.cn\/#\/schema\/person\/c292b26c0a3311036ce0f5ab28a1ea05","name":"xpharmanews","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","caption":"xpharmanews"},"url":"https:\/\/xpharma.com.cn\/index.php\/author\/xpharmanews\/"}]}},"_links":{"self":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3768","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/comments?post=3768"}],"version-history":[{"count":1,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3768\/revisions"}],"predecessor-version":[{"id":3770,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/3768\/revisions\/3770"}],"wp:attachment":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/media?parent=3768"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/categories?post=3768"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/tags?post=3768"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}